Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton S, Fenaux P, Yee K, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. de Botton S, et al. Among authors: taussig dc. Blood Adv. 2023 Jul 11;7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411. Blood Adv. 2023. PMID: 36724515 Free PMC article.
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, Latif AL, Cahalin P, Aries J, Amer M, Belsham E, Conneally E, Craddock C, Culligan D, Dennis M, Duncan C, Freeman SD, Furness C, Gilkes A, Gkreka P, Hodgson K, Ingram W, Jain M, King A, Knapper S, Kottaridis P, McMullin MF, Mohite U, Ngu L, O'Nions J, Patrick K, Rider T, Roberts W, Severinsen MT, Storrar N, Taylor T, Russell NH, Dillon R. Othman J, et al. Leukemia. 2023 Oct;37(10):2066-2072. doi: 10.1038/s41375-023-01994-x. Epub 2023 Aug 9. Leukemia. 2023. PMID: 37558736 Free PMC article.
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study.
Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puyó P, Micalizzi C, Rossig C, Shukla N, Gilad G, Locatelli F, Baruchel A, Zwaan CM, Bezler NS, Rubio-San-Simón A, Taussig DC, Raetz EA, Mao ZJ, Wood BL, Alvarez Arias D, Krevvata M, Nnane I, Bandyopadhyay N, Lopez Solano L, Dennis RM, Carson R, Vora A. Bhatla T, et al. Among authors: taussig dc. Blood. 2024 Nov 21;144(21):2237-2247. doi: 10.1182/blood.2024024493. Blood. 2024. PMID: 39158071 Clinical Trial.
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Sekeres MA, Montesinos P, Novak J, Wang J, Jeyakumar D, Tomlinson B, Mayer J, Jou E, Robak T, Taussig DC, Dombret H, Merchant A, Shaik N, O'Brien T, Roh W, Liu X, Ma W, DiRienzo CG, Chan G, Cortes JE. Sekeres MA, et al. Among authors: taussig dc. Leukemia. 2023 Oct;37(10):2017-2026. doi: 10.1038/s41375-023-02001-z. Epub 2023 Aug 21. Leukemia. 2023. PMID: 37604981 Free PMC article. Clinical Trial.
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.
Casado P, Rio-Machin A, Miettinen JJ, Bewicke-Copley F, Rouault-Pierre K, Krizsan S, Parsons A, Rajeeve V, Miraki-Moud F, Taussig DC, Bödör C, Gribben J, Heckman C, Fitzgibbon J, Cutillas PR. Casado P, et al. Among authors: taussig dc. Signal Transduct Target Ther. 2023 Feb 27;8(1):80. doi: 10.1038/s41392-022-01288-1. Signal Transduct Target Ther. 2023. PMID: 36843114 Free PMC article.
A global study for acute myeloid leukemia with RARG rearrangement.
Zhu HH, Qin YZ, Zhang ZL, Liu YJ, Wen LJ, You MJ, Zhang C, Such E, Luo H, Yuan HJ, Zhou HS, Liu HX, Xu R, Li J, Li JH, Hao JP, Jin J, Yu L, Zhang JY, Liu LP, Zhang LP, Huang RB, Shen SH, Gao SJ, Wang W, Yan XJ, Zhang XY, Du X, Chu XX, Yu YF, Wang Y, Mi YC, Lu Y, Cai Z, Su Z, Taussig DC, MacMahon S, Ball ED, Wang HY, Welch JS, Yin CC, Borthakur G, Sanz MA, Kantarjian HM, Huang JY, Hu J, Chen SN. Zhu HH, et al. Among authors: taussig dc. Blood Adv. 2023 Jul 11;7(13):2972-2982. doi: 10.1182/bloodadvances.2022008364. Blood Adv. 2023. PMID: 36799929 Free PMC article.
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.
Iland HJ, Russell N, Dillon R, Schuh AC, Tedjaseputra A, Wei A, Khwaja A, Knapper S, Lane SW, Reynolds J, McMullin MF, Martin A, Tan P, Taussig DC, Wong A, Taper J, Fraga C, Kelly R, Tawana K, Mehta P, Mina A, Altman JK, Mølle I, Tauro S, Tholouli E. Iland HJ, et al. Among authors: taussig dc. Blood Adv. 2023 Jun 13;7(11):2580-2585. doi: 10.1182/bloodadvances.2022007126. Blood Adv. 2023. PMID: 36075018 Free PMC article. No abstract available.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. Zeidan AM, et al. Among authors: taussig dc. Blood Adv. 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. Blood Adv. 2022. PMID: 34933333 Free PMC article. Clinical Trial.
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS, Dillon R, Ivey A, Teh TC, Nguyen P, Cummings N, Taussig DC, Latif AL, Potter NE, Runglall M, Russell NH, Raj K, Schwarer AP, Fong CY, Grigg AP, Wei AH. Tiong IS, et al. Among authors: taussig dc. Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26. Br J Haematol. 2021. PMID: 32458446 Free PMC article.
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
Moore AS, Faisal A, Mak GWY, Miraki-Moud F, Bavetsias V, Valenti M, Box G, Hallsworth A, de Haven Brandon A, Xavier CPR, Stronge R, Pearson ADJ, Blagg J, Raynaud FI, Chopra R, Eccles SA, Taussig DC, Linardopoulos S. Moore AS, et al. Among authors: taussig dc. Blood Adv. 2020 Apr 14;4(7):1478-1491. doi: 10.1182/bloodadvances.2019000986. Blood Adv. 2020. PMID: 32282883 Free PMC article.
29 results